Updating results

92 results for valproate Sort: Relevance | Date

ESUOM41: Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations

Summary of the evidence on valproate preparations for managing aggression, agitation and behavioural disturbances in people dementia..

Evidence summary Published March 2015

Bipolar disorder: assessment and management (CG185)

Evidence-based recommendations on assessing and managing bipolar disorder in children, young people and adults

Clinical guideline Published September 2014 Last updated February 2016

Epilepsies: diagnosis and management (CG137)

Evidence-based recommendations on diagnosing, treating and managing epilepsy in children, young people and adults

Clinical guideline Published January 2012 Last updated February 2016

Antenatal and postnatal mental health: clinical management and service guidance (CG192)

Evidence-based recommendations on the recognition, assessment, care and treatment of antenatal and postnatal mental health problems in women

Clinical guideline Published December 2014 Last updated August 2017

Antenatal and postnatal mental health

Everything NICE has said on antenatal and postnatal mental health in an interactive flowchart

NICE Pathway Published November 2011 Last updated August 2017

Bipolar disorder

Everything NICE has said on recognising, assessing and managing bipolar disorder in children, young people and adults in an interactive flowchart

NICE Pathway Published September 2014 Last updated February 2017

Do not start valproate in primary care to treat bipolar disorder.

Do Not Do Recommendation   Do not start valproate in primary care to treat bipolar disorder. Do Not Do Recommendation Details

Do not do recommendation Published June 2016

ESNM17: Partial-onset seizures in epilepsy: zonisamide as monotherapy

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

ESUOM40: Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

Do not routinely measure plasma valproate levels unless there is evidence of ineffectiveness, poor adherence or toxicity.

Do Not Do Recommendation   Do not routinely measure plasma valproate levels unless there is evidence ofineffectiveness, poor...

Do not do recommendation Published June 2016

Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used routinely] as there is insufficient evidence for their use.

Do Not Do Recommendation   Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should...

Do not do recommendation Published June 2015

ESNM37: Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

ESNM7: Partial-onset seizures in epilepsy: perampanel as adjunctive treatment

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Only offer felbamate in centres providing tertiary epilepsy specialist care and when treatment with sodium valproate, lamotrigine, rufinamide and topiramate have proven ineffective or not tolerated.

 sodium valproate, lamotrigine, rufinamide and topiramate have proven ineffective or not tolerated. Do Not Do...

Do not do recommendation Published June 2016

How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?

treat mental health problems may carry some risk for the woman, fetus and baby. For some drugs such as sodium valproate these risks are...

Research recommendation Published July 2017

Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

Evidence-based recommendations on the pharmacological management of neuropathic pain in adults in non-specialist settings

Clinical guideline Published November 2013 Last updated February 2017

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)

Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Interventional procedures guidance Published March 2016

Epilepsy

Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart

NICE Pathway Published January 2012 Last updated August 2017

Do not start regular combined antipsychotic medication, except for short periods (for example, when changing medication)

not start valproate in primary care to treat bipolar disorder. Do not offer lamotrigine to treat mania Do not

Do not do recommendation Published June 2016

Do not offer gabapentin or topiramate to treat bipolar disorder.

arrangements. Do not start valproate in primary care to treat bipolar disorder. Do not offer lamotrigine to treat mania

Do not do recommendation Published June 2016

Do not routinely continue antipsychotic treatment in young people for longer than 12 weeks.

lithium before, except under shared-care arrangements. Do not start valproate in primary care to treat bipolar disorder

Do not do recommendation Published June 2016

Do not routinely measure plasma lamotrigine levels unless there is evidence of ineffectiveness, poor adherence or toxicity.

. Do not start valproate in primary care to treat bipolar disorder. Do not offer lamotrigine to treat mania

Do not do recommendation Published June 2016

Do not offer lamotrigine to treat mania

for people who have not taken lithium before, except under shared-care arrangements. Do not start valproate in primary care

Do not do recommendation Published June 2016

Do not use questionnaires in primary care to identify bipolar disorder in adults.

primary care for people who have not taken lithium before, except under shared-care arrangements. Do not start valproate in

Do not do recommendation Published June 2016

Do not use questionnaires in primary care to identify bipolar disorder in children or young people.

. Do not start valproate in primary care to treat bipolar disorder. Do not offer lamotrigine to treat mania Do

Do not do recommendation Published June 2016

Do not start lithium to treat bipolar disorder in primary care for people who have not taken lithium before, except under shared-care arrangements.

. Do not start valproate in primary care to treat bipolar disorder. Do not offer lamotrigine to treat mania

Do not do recommendation Published June 2016

ESUOM13: Gastroparesis in adults: oral erythromycin

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Augmentation of an antidepressant with pindolol* or thyroid hormones* [should not be used routinely] as there is inconsistent evidence of effectiveness

. Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used routinely] as there...

Do not do recommendation Published June 2015

When prescribing drugs other than serotonin reuptake inhibitors (SSRIs), dosulepin should not be prescribed.

intervention. Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used

Do not do recommendation Published June 2015

Do not switch to, or start, dosulepin because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose.

. Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used routinely] as there

Do not do recommendation Published June 2015

Do not use electroconvulsive therapy (ECT) routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.

valproate* [should not be used routinely] as there is insufficient evidence for their use. Augmentation of an antidepressant with

Do not do recommendation Published June 2015

Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.

. Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used routinely] as there...

Do not do recommendation Published June 2016

Medication management as a separate intervention for people with depression should not be provided routinely by services. It is likely to be effective only when provided as part of a more complex intervention.

. Augmentation of an antidepressant with buspirone*, carbamazepine*, lamotrigine* or valproate* [should not be used routinely] as there...

Do not do recommendation Published June 2015

The progestogen-only pill is not recommended as reliable contraception in women and girls taking enzyme-inducing anti epileptic drugs (AEDs).

unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least...

Do not do recommendation Published June 2015

Do not offer carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, pregabalin, tiagabine or vigabatrin as adjunctive treatment in children, young people and adults with Dravet syndrome.

(Gastaut type) Levetiracetam is not cost effective at June 2011 unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate...

Do not do recommendation Published June 2016

The EEG should not be used to exclude a diagnosis of epilepsy in a child, young person or adult in whom the clinical presentation supports a diagnosis of a non-epileptic event.

unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least...

Do not do recommendation Published June 2015

There is insufficient evidence to recommend the routine use of joint epilepsy and obstetric clinics, although they may be convenient for mothers and healthcare professionals.

. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least 50% of June...

Do not do recommendation Published June 2016